Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
March 27, 2024 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 20, 2024 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
March 14, 2024 16:01 ET
|
Vaxart, Inc.
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
March 07, 2024 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
March 06, 2024 08:00 ET
|
Vaxart, Inc.
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”)...
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
February 05, 2024 08:00 ET
|
Vaxart, Inc.
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
January 19, 2024 08:30 ET
|
Vaxart, Inc.
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by...
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
January 16, 2024 09:25 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for...
Vaxart, Inc. Announces Management Change
January 16, 2024 09:22 ET
|
Vaxart, Inc.
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
December 21, 2023 08:00 ET
|
Vaxart, Inc.
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and...